Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
Document Type and Number:
WIPO Patent Application WO/2011/161232
Kind Code:
A1
Abstract:
The present invention relates to an improved method for the preparation of 3-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}- ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid. The present invention also relates to a new compound, namely tert-butyl (methyl-{2-[2-(methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate, used in this improved method.

Inventors:
GOVAERTS, Tom, Cornelis, Hortense (Werchtersesteenweg 165, Betekom, B-3130, BE)
BONGARTZ, Jean-Pierre, André, Marc (Driezenstraat 2 bus 2, Turnhout, B-2300, BE)
NIESTE, Patrick, Hubert, J. (Prelaat Verbraekenlaan 9, Westerlo, B-2260, BE)
Application Number:
EP2011/060606
Publication Date:
December 29, 2011
Filing Date:
June 24, 2011
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
TIBOTEC PHARMACEUTICALS (Eastgate Village, EastgateLittle Island, Co Cork, IE)
GOVAERTS, Tom, Cornelis, Hortense (Werchtersesteenweg 165, Betekom, B-3130, BE)
BONGARTZ, Jean-Pierre, André, Marc (Driezenstraat 2 bus 2, Turnhout, B-2300, BE)
NIESTE, Patrick, Hubert, J. (Prelaat Verbraekenlaan 9, Westerlo, B-2260, BE)
International Classes:
C07D223/14
Attorney, Agent or Firm:
DAELEMANS, Frank (Turnhoutseweg 30, Beerse, B-2340, BE)
Download PDF:
Claims:
Claims

1. Method for the preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2- {2-[methyl- (sulphamoyl)-amino]-ethoxy} -ethyl)-carbamoyl]-7H-indolo-[2, 1 -a]-[2]- benzazepine-10-carboxylic acid ('Compound A'), characterized in that it comprises the following steps:

a) 1 O-(fcrt-butoxycarbonyl)- 13-cyclohexyl-3-methoxy- 7H-indolo-[2, 1 -a]-[2]- benzazepine-6-carboxylic acid (Compound I) is reacted with te/ -butyl (methyl- {2-[2-(methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate

(Compound 'B') in the presence of a coupling agent in a suitable solvent, and

b) Compound (II) thus obtained is hydrolysed with an acid, so that Compound 'A' is obtained.

2. Method according to Claim 1 , where Steps a) and b) are carried out as a one-vessel synthesis. 3. Method according to Claim 1 or 2, where the coupling agent is chosen from

amongst carbodiimidazole (CDI), dicyclohexylcarbodiimide (DCC), 0-(7- azabenzotriazo le- 1 -yl)- 1 , 1 ,3 ,3-tetramethyluronium hexafluorophosphate (HATU), bromotri-(pyrrolidino)-phosphonium hexafluorophosphate (PyBrOP), and a combination of 1-hydroxybenztriazole hydrate (HOBT.H20) and l-ethyl-3-(3- dimethylaminopropyl)-carbodiimide hydrochloride (EDCI).

4. Method according to any one of Claims 1-3, where the acid used in Step b) is

trifluoroacetic acid, methanesulphonic acid, hydrogen chloride, hydrogen bromide, ;?<2ra-toluenesulphonic acid, sulphuric acid or phosphoric acid. 5. Method according to any one of Claims 1-4, where the preparation is carried out in a nitrogen atmosphere. 6. Method according to Claim 5, where the solvent used in Step a) is

2-methyltetrahydrofuran.

7. Method according to Claim 6, where the organic acid used in Step b) is

methanesulphonic acid, the reaction temperature is 50°C, and the duration of the reaction is no longer than 5 hours. 8. tert-Butyl (methyl- {2-[2-(methylamino)-ethoxy]-ethyl} -sulphamoyl)-carbamate, and acid-addition salts thereof.

Description:
PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2- [METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H- INDOLO-[2, 1 -a]-[2]-BENZAZEPINE- 10-CARBOXYLIC ACID

The present invention relates to an improved method for the preparation of

13-cyclohexyl-3-methoxy-6-[methyl-(2- {2-[methyl-(sulphamoyl)-amino]-ethoxy} - ethyl)-carbamoyl]-7H-indolo-[2,l-a]-[2]-benzazepine-10-carbo xylic acid. The present invention also relates to a new compound, namely tert-butyl (methyl- {2- [2- (methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate, used in this improved method.

13-Cyclohexyl-3-methoxy-6-[methyl-(2- {2-methyl-(sulphamoyl)- amino]-ethoxy} -ethyl)-carbamoyl]-7H-indolo-[2, 1 -a]-[2]- benzazepine-10-carboxylic acid

Compound 'A'

fert-Butyl (methyl- {2-[2-(methylamino)-ethoxy]-ethyl} - sulphamoyl)-carbamate

Compound 'B'

WO 2010 / 003658 describes some macrocyclic indoles that can be used as inhibitors of the hepatitis C virus. The synthesis of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2- [methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-ind olo-[2,l- ]-[2]- benzazepine-10-carboxylic acid (Compound Ά') was described there on pages 38 and 39 (see Compound le) as a three-step synthesis, giving an overall yield of 62%.

The aim of the present invention is to provide an improved method for the synthesis of 13-cyclohexyl-3-methoxy-6-[methyl-(2- {2-[methyl-(sulphamoyl)-amino]-ethoxy } - ethyl)-carbamoyl]-7H-indolo-[2,l-(3]-[2]-benzazepine-10-carb oxylic acid (Compound ' A') that is easier to carry out and is more efficient than the method known so far.

The present invention achieves this aim by providing an improved method for the preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2- (2-[methyl-(sulphamoyl)- amino] -ethoxy} -ethyl)-carbamoyl]-7H-indolo-[2, l-a]-[2]-benzazepine-l 0-carboxylic acid ('Compound A'), characterized in that it comprises the following steps:

a) 10-(tert-butoxycarbonyl)- 13-cyclohexyl-3-methoxy- 7H-indolo-[2, 1 -a]-[2]- benzazepine-6-carboxylic acid (Compound I) is reacted with tert-butyl (methyl- {2-[2-(methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate (Compound 'B') in the presence of a coupling agent in a suitable solvent

( D 'B'

and Compound (II) thus obtained is hydrolysed with an acid to prepare Compound Ά'.

The coupling agent in Step a) is e.g. carbodiimidazole (CDI), dicyclohexylcarbodiimide (DCC), 0-(7-azabenztriazolo- 1 -yl)- 1,1,3 ,3-tetramethyluronium hexafluorophosphate (HATU), bromotri-(pyrrolidino)-phosphonium hexafluorophosphate (PyBrOP), a combination of 1-hydroxybenztriazole hydrate (HOBt.H 2 0) and l-ethyl-3-(3- dimethylaminopropyl)-carbodiimide hydrochloride (EDCI).

A suitable solvent in Step a) is e.g. dichloromethane, 2-methyltetrahydrofuran, acetonitrile, acetone, 2-butanone, 4-methyl-2-pentanone, ethyl acetate, isopropyl acetate or toluene.

The hydrolysis in Step b) can be carried out by using trifluoroacetic acid,

methanesulphonic acid, hydrogen chloride, hydrogen bromide, /?ara-toluenesulphonic acid, sulphuric acid or phosphoric acid.

Steps a) and b) can be carried out as a two-step synthesis, in which Compound (II) is isolated in Step a) before carrying out Step b), or else Steps a) and b) are conducted as a one- vessel synthesis.

The overall yield obtained in Steps a) and b) is between 86 and 91%, depending on which of the procedures described in Examples 3, 4 and 5 (Experiment B) is used to carry out the new method. The present invention also relates to a new compound (Compound 'B') with the following formula, and possible acid-addition salts thereof:

fe^Butyl-(methyl-{2-[2-(methylamino)-ethoxy]-ethyl}-sulphamo yl)-carbamate (Compound 'B')

The acid-addition salts of Compound 'B' include the salts that Compound 'B' can form with organic or inorganic acids, such as mineral acids, sulphonic acids, carboxylic acids and phosphorus-containing acids. Examples of salt-forming mineral acids are hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid, sulphuric acid, nitric acid, chloric acid, perchloric acid and phosphoric acid. Salt-forming sulphonic acids are toluenesulphonic acid, benzenesulphonic acid, methanesulphonic acid and trifluormethanesulphonic acid. Salt-forming carboxylic acids are formic acid, acetic acid, propionic acid, butanoic acid and the like. Salt-forming dicarboxylic acids are oxalic acid, malonic acid, succinic acid, glutaric acid and the like. Salt-forming hydroxy-acids are glycollic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid and the like. Other salt-forming carboxylic acids are trifluoroacetic acid, benzoic acid, chloroacetic acid, phthalic acid, maleic acid and malonic acid.

Phosphorus-containing acids are various phosphono-acids, phosphonic acids and phosphinic acids.

This new Compound 'B' can be synthesized as follows:

Step 1 :

Experimental

The following abbreviations are used here:

A/A: active yield

CDI: carbony ldiimidazo le

CSI: chlorosulphonyl isocyanate

DBU: l,8-diaza-bicyclo-[5,4,0]-undecene-7

DIPE: diisopropyl ether

DMAP: 4-dimethylaminopyridine

DME: 1 ,2-dimethoxyethane

DMSO-d6: deuterated dimethylsulphoxide

EDCI: 1 -ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride

F/F: physical yield

HOBt: 1-hydroxybenzotriazole hydrate

iPrOAc: isopropyl acetate

LC: liquid chromatography

MeCN: acetonitrile

MEK: methyl ethyl ketone (2-butanone)

MeTHF: 2-methyltetrahydrofuran

MeS03H: methanesulphonic acid

MIK: methyl isopropyl ketone

MTBE: methyl tert-butyl ether

NMR: nuclear magnetic resonance

tBuOH: tert-butanol

tBOC: tert-butoxycarbonyl

THF: tetrahydrofuran Example 1

Intermediate (1)

A solution of 8.205 g of chlorosulphonyl isocyanate (58.0 mmol, 1 Eq) in 50 ml of acetonitrile (1 litre/mo 1) was cooled to -2°C on an ice/salt bath under nitrogen, using a 500-ml four-neck flask fitted with a thermometer, a magnetic stirrer and a dropping (addition) funnel. A solution of 4.297 g of tert-butanol (58.0 mmol, 1 Eq) in 33 ml of acetonitrile (0.5 1/mol) was added dropwise over 20 minutes, with the temperature remaining below 4°C. Four minutes later (when the temperature had dropped to 1°C), a solution of DMAP (116.0 mmol, 2 Eq) in 55 ml of acetonitrile (1 litre/mol) was added dropwise over 24 minutes, with the temperature remaining below 5°C.

The solution was allowed to stand for 65 minutes to ensure the best crystallization, with the temperature remaining below 3°C. The white suspension was filtered on a Buchner funnel filter, giving a non-tacky white powder. The precipitate was dried overnight in a drying cabinet at 40°C under vacuum, which gave 9.465 g of Intermediate (I).

Example 2

Compound 'B'

109.1 g (0.825 mol) of l,5-bis-(methylamino)-3-oxapentane and 1.5 litres of acetonitrile were introduced into a reaction vessel with an inert atmosphere. The resulting solution was cooled to 0°C, and 226 g (0.75 mol) of Intermediate (1) was added to it. The mixture thus obtained was stirred first for 6 hours at 10°C, and then for 3 days at 0°C. The precipitate was filtered off and washed with acetonitrile. After drying at 25°C, Compound 'B' was obtained in a yield of 95 g (40.6%, corrected for purity) in the form of white crystals. Example 3

Intermediate (2)

0.400 g (0.82 mmol, 1 Eq) of 10-(tert-butoxycarbonyl)-13-cyclohexyl-3-methoxy-7H- indolo-[2,l-a]-[2]-benzazepine-6-carboxylic acid (called Compound lb on page 38 of WO 2010 / 003658), 0.164 g of HOBt (1.07 mmol, 1.3 Eq) and 0.201g of EDCI (1.07 mmol, 1.3 Eq) were dissolved in 6.5 ml of MeTHF (8 1/mol) in a closed glass flask. The contents of the flask were stirred for 1 hour at room temperature. 0.469 g of Compound 'B' (64.3 wt-%, 0.98 mmol, 1.2 Eq) was then added to the reaction mixture, which was analysed after a reaction time of 18 hours. Analysis by LC indicated that

Intermediate (2) had been obtained in a yield of 93.1 %.

Example 4

Intennediate (2)

12.00 g (24.61 mmol, 1 Eq) of 10-(tert-butoxycarbonyl)-13-cyclohexyl-3-methoxy-7H- indolo-[2,l-a]-[2]-benzazepine-6-carboxylic acid, 4.92 g of HOBt (31.99 mmol, 1.3 Eq) and 6.03 g of EDCI (31.99 mmol, 1.3 Eq) were introduced into a 100-ml flask and dissolved in 200 ml of MeTHF (8 1 mol). The contents of the flask were stirred for 1 hour at room temperature. Then 11.663 g of Compound 'B' (77.4 wt-%, 29.53 mmol, 1.2 Eq) was added, and the reaction mixture was analysed after a reaction time of 18 hours. Analysis by LC indicated that Intermediate (2) had been obtained in a yield of 98.3%.

The reaction mixture was then extracted and washed first with two 180-ml portions of H 2 0 (15 1/mol), and then with two 180-ml portions of an NaHC0 3 solution (15 1/mol). The organic layer was dried with 2.4 g of Na 2 S0 4 and filtered, after which the volume of the filtrate obtained was determined. 60 ml of MeTHF was added to make up the volume to 200 ml (81/M). Analysis by LC indicated that Intermediate (2) had been obtained in a yield of 93.7%.

Example 5

Compound 'A'

Experiment A

To 13.722 g of Intermediate (2) (16.4 wt-%, 1 Eq, 2.88 mmol) dissolved in MeTHF (8 1/mol) in a 100-ml flask without a nitrogen atmosphere(this solution contained 2.17 wt-% of water), 251 μΐ of water was added to bring the water content up to 4 wt-%. After the addition of 1.9 ml of MeS0 3 H (1 Eq, 28.8 mmol), the reaction mixture was placed on an oil bath heated to 50°C. A sample was taken and analysed after a reaction time of 5 hours. After a reaction time of 22 hours, the reaction mixture was brought to room temperature, and sampled again for analysis. The whole reaction mixture weighed 15.022 g.

Analysis by LC

After 5 hours: 90.1% of Compound 'A'

After 22 hours: 75.4% of Compound 'A' Experiment B

119.6 g of Intermediate (2) (10.27 wt-%, 15.7 mmol, 1 Eq) was dissolved in MeTHF (8 1/mol) in a reaction vessel with a nitrogen atmosphere. The solution contained 2.21 wt-%) of water. 2.81 g of water were added to bring the water content up to 4 wt-%. After the addition of 10.31 ml of MeS0 3 H (157 mmol, 10 Eq), the reaction mixture was heated to 50°C. After a reaction time of 5 hours, the reaction mixture was cooled to room temperature, and a sample of it was analysed. The whole reaction mixture weighed 1 19.6 g.

Analysis by LC